Respiratory viral infections therapeutic - Lumen Bioscience
Latest Information Update: 31 May 2023
At a glance
- Originator Lumen Bioscience
- Class Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 11 May 2023 Lumen Bioscience has worldwide patent protection for its proprietary drug development technology platform (Lumen Bioscience pipeline, May 2023)
- 11 May 2023 Early research in Viral infections (Prevention) in USA (Intranasal)
- 11 May 2023 Early research in Viral infections in USA (Intranasal)